All In Biotech

Drug Trial Radar · NCT06513546

A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients

A Multi-centre, Phase 1/2, Randomised, Double-blind, Placebo Controlled Study With an Optional Open-label Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics of PLL001 for the Treatment of ALS

Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 153 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

153

Planned (sponsor's estimate)

Start

Apr 8, 2026

Primary completion

Dec 15, 2026

Study completion Jun 15, 2027

Sponsor

Lead sponsor
PLL TX AUSTRALIA PTY LTDIndustry
Sponsor type
Industry
First posted
Jul 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

FIH, Phase 1/2, multi-centre, randomised, double-blind, placebo controlled study with an optional open-label dosing extension to assess the safety, tolerability, efficacy, and Pharmacodynamics (PD) of single or multiple (up to 48 weeks QD) subcutaneous (SC) doses of PLL001 compared to placebo in subjects diagnosed with ALS.

Conditions

  • Amyotrophic Lateral Sclerosis
  • ALS

Interventions

  • PLL001 or placebo daily subcutaneous injectionsDrug

    PLL001 consists of the combination of 4 drug substances (DS) each being a linear poly-lysine flexible backbone with an average length of 70 L-lysines linked with 10% of conjugated side chains all being small chain fatty acids (SCFAs) (acetate, butyrate, lactate and propionate). The remaining 90% of the lysine residues are present as bromide salt. PLL001 DP is presented as 20 mL vials containing 16 mL of a sterilised solution for SC injection with the following formula (5× concentration)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: safetyTime frame: 7 days
  2. Part 2: efficacy of PLL001 compared to placebo after 8, 16, and 24 weeks of once daily (QD) treatmentTime frame: 24 weeks
  3. Part 2: survival after 8, 16, and 24 weeks of QD treatment for PLL001 compared to placeboTime frame: 24 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.